Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder

NCT02621151 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Muscle-invasive Urothelial Cancer of the Bladder

Interventions

BIOLOGICAL: Pembrolizumab
PROCEDURE: Transurethral Resection of Bladder Tumor
DRUG: Gemcitabine
RADIATION: External Beam Radiation Therapy

Sponsor

NYU Langone Health

Collaborators

[object Object]